{"result": {"id": "7685dd43-3de7-4253-b5c1-10b0871efd80", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>EUROPACE<|>ORGANIZATION<|>A medical journal publishing research articles on heart rhythm and atrial fibrillation>  \n##  \n(\"entity\"<|>J HYPERTENS<|>ORGANIZATION<|>A medical journal publishing research articles on hypertension>  \n##  \n(\"entity\"<|>INT J HYPERTENS<|>ORGANIZATION<|>A medical journal publishing research articles on hypertension>  \n##  \n(\"entity\"<|>HYPERTENSION<|>ORGANIZATION<|>A medical journal publishing research articles on hypertension>  \n##  \n(\"entity\"<|>AUTON NEUROSCI<|>ORGANIZATION<|>A medical journal publishing research articles on autonomic neuroscience>  \n##  \n(\"entity\"<|>AM J HYPERTENS<|>ORGANIZATION<|>A medical journal publishing research articles on hypertension>  \n##  \n(\"entity\"<|>BMJ OPEN<|>ORGANIZATION<|>A medical journal publishing open-access research articles>  \n##  \n(\"entity\"<|>J CARDIOL<|>ORGANIZATION<|>A medical journal publishing research articles on cardiology>  \n##  \n(\"entity\"<|>LANCET<|>ORGANIZATION<|>A prestigious medical journal publishing research on various medical topics>  \n##  \n(\"entity\"<|>MEDICINA (KAUNAS)<|>ORGANIZATION<|>A medical journal publishing research articles on various medical topics>  \n##  \n(\"entity\"<|>AM J CARDIOL<|>ORGANIZATION<|>A medical journal publishing research articles on cardiology>  \n##  \n(\"relationship\"<|>STEFFEL J<|>EUROPACE<|>Steffel J published research in Europace<|>5>  \n##  \n(\"relationship\"<|>PALATINI P<|>J HYPERTENS<|>Palatini P published research in J Hypertens<|>5>  \n##  \n(\"relationship\"<|>DALAL J<|>INT J HYPERTENS<|>Dalal J published research in Int J Hypertens<|>5>  \n##  \n(\"relationship\"<|>GRASSI G<|>HYPERTENSION<|>Grassi G published research in Hypertension<|>5>  \n##  \n(\"relationship\"<|>SERAVALLE G<|>AUTON NEUROSCI<|>Seravalle G published research in Auton Neurosci<|>5>  \n##  \n(\"relationship\"<|>PALATINI P<|>AM J HYPERTENS<|>Palatini P published research in Am J Hypertens<|>5>  \n##  \n(\"relationship\"<|>ZHAO MX<|>BMJ OPEN<|>Zhao MX published research in BMJ Open<|>5>  \n##  \n(\"relationship\"<|>ZHANG M<|>J CARDIOL<|>Zhang M published research in J Cardiol<|>5>  \n##  \n(\"relationship\"<|>SWEDBERG K<|>LANCET<|>Swedberg K published research in Lancet<|>5>  \n##  \n(\"relationship\"<|>TSAI ML<|>MEDICINA (KAUNAS)<|>Tsai ML published research in Medicina (Kaunas)<|>5>  \n##  \n(\"relationship\"<|>KJEKSHUS JK<|>AM J CARDIOL<|>Kjekshus JK published research in Am J Cardiol<|>5>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559068, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 792, "prompt_tokens": 6277, "total_tokens": 7069, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 6208}, "prompt_cache_hit_tokens": 6208, "prompt_cache_miss_tokens": 69}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ]. N EnglJ Med,  2011,365(10) :883-891.\n[363]  GrangerCB, AlexanderJH, McMurrayJJ, etal. Apixabanver- suswarfarininpatientswithatrialfibrillation[J]. NEnglJMed,  2011,365(11) :981-992.\n[364]  GiuglianoRP, RuffCT, BraunwaldE, etal.  Edoxaban versus warfarin in patients with atrialfibrillation[J]. N EnglJ Med,  2013,369(22) :2093-2104.\n[365]  SteffelJ, CollinsR, AntzM, etal.  2021European HeartRhythm  Association practicalguide on the use ofnon-vitamin K antago- nistoralanticoagulantsinpatientswithatrialfibrillation[J]. Eu- ropace,2021,23(10) :1612-1676.\n[366]  KirchhofP, Camm AJ, GoetteA, etal.  Early rhythm-control therapyin patients with atrialfibrillation[J]. N EnglJ Med,  2020,383(14) :1305-1316.\n\n\n\n[367]  PalatiniP, RoseiEA, CasigliaE, etal. Managementofthehy- pertensive patientwithelevatedheartrate: statementofthesec- ond consensus conference endorsed by the European Society of Hypertension[J]. J Hypertens,2016,34(5) :813-821.\n[368]  DalalJ, DasbiswasA, SathyamurthyI, etal.  Heartratein hy- pertension: review and expert opinion[J].  Int J Hypertens,  2019:2087064.\n[369]  高血压心率管理多学科共识组.  中国高血压患者心率管理多学 科专家共识(2021年版)[J]. 中国医学前沿杂志(电子版) ,2021, 13(4) :38-48.\n[370]  孙宁玲 ,霍勇 ,黄峻.  中国高血压患者心率现状调查[J]. 中华高 血压杂志 ,2015,23(10) :934-939.\n[371]  GrassiG, PisanoA, BolignanoD, etal. Sympatheticnervetraf- fic activation in essentialhypertension and its correlates:  sys- tematic reviews and meta-analyses[J]. Hypertension, 2018, 72\n(2) :483-491.\n[372]  SeravalleG, GrassiG.  Sympatheticnervous system and hyper- tension: new evidences[J]. Auton Neurosci,2022,238:102954.\n[373]  Esler M,  Lambert G, Esler D, et al.  Evaluation of elevated heartrateasa sympatheticnervous system biomarkerin essen- tialhypertension[J]. J Hypertens,2020,38(8) :1488-1495.\n[374]  PalatiniP.  Resting heart rate as a cardiovascular risk factor in hypertensivepatients: an update[J]. Am J Hypertens, 2021, 34\n(4) :307-317.\n[375]  Zhao MX, Zhao Q, ZhengM, etal. Effectofrestingheartrate on therisk ofall-causedeathin Chinesepatientswithhyperten- sion: analysis of the Kailuan follow-up study[J]. BMJ Open,  2020,10(3) :e032699.\n[376]  ZhangM, Han C, Wang C, etal.  Association ofresting heart rate and cardiovascular disease mortality in hypertensive and normotensiveruralChinese[J]. J Cardiol,2017,69(5) :779-784.\n[377]  SwedbergK, KomajdaM, B?hm M, etal. Ivabradineand out- comesin chronicheartfailure(SHIFT) : a randomised placebo- controlled study[J]. Lancet,2010,376(9744) :875-885.\n[378]  B?hm M, SwedbergK, KomajdaM, etal.  Heartrateasa risk factorinchronicheartfailure(SHIFT) : theassociationbetween heartrateand outcomesin a randomized placebo-controlled trial [J]. Lancet,2010,376(9744) :886-894.\n[379]  TsaiML, LinSI, KaoYC, etal. Optimalheartratecontrolim- proveslong-term prognosis ofdecompensated heartfailure with reduced ejection fraction[J]. Medicina (Kaunas) , 2023, 59(2) :  348.\n[380]  KjekshusJK.  Importanceofheartrateindeterminingbeta-bloc- kerefficacy in acute and long-term acute myocardial infarction intervention trials[J]. Am JCardiol,1986,57(12) :43F-49F.\n[381]  CucheratM.  Quantitativerelationshipbetweenrestingheartrate reduction and magnitude of clinicalbenefits in post-myocardial\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>N ENGLJ MED<|>ORGANIZATION<|>A medical journal publishing research articles on various medical topics including atrial fibrillation and hypertension>  \n##  \n(\"entity\"<|>GRANGER CB<|>PERSON<|>A researcher involved in studies comparing Apixaban and Warfarin in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>ALEXANDER JH<|>PERSON<|>A researcher involved in studies comparing Apixaban and Warfarin in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>MCMURRAY JJ<|>PERSON<|>A researcher involved in studies comparing Apixaban and Warfarin in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>GIUGLIANO RP<|>PERSON<|>A researcher involved in studies comparing Edoxaban and Warfarin in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>RUFF CT<|>PERSON<|>A researcher involved in studies comparing Edoxaban and Warfarin in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>BRAUNWALD E<|>PERSON<|>A researcher involved in studies comparing Edoxaban and Warfarin in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>STEFFEL J<|>PERSON<|>A researcher involved in studies on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>COLLINS R<|>PERSON<|>A researcher involved in studies on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>ANTZ M<|>PERSON<|>A researcher involved in studies on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>KIRCHHOF P<|>PERSON<|>A researcher involved in studies on early rhythm-control therapy in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>CAMM AJ<|>PERSON<|>A researcher involved in studies on early rhythm-control therapy in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>GOETTE A<|>PERSON<|>A researcher involved in studies on early rhythm-control therapy in patients with atrial fibrillation>  \n##  \n(\"entity\"<|>PALATINI P<|>PERSON<|>A researcher involved in studies on the management of hypertensive patients with elevated heart rate>  \n##  \n(\"entity\"<|>ROSEI EA<|>PERSON<|>A researcher involved in studies on the management of hypertensive patients with elevated heart rate>  \n##  \n(\"entity\"<|>CASIGLIA E<|>PERSON<|>A researcher involved in studies on the management of hypertensive patients with elevated heart rate>  \n##  \n(\"entity\"<|>DALAL J<|>PERSON<|>A researcher involved in studies on heart rate in hypertension>  \n##  \n(\"entity\"<|>DASBISWAS A<|>PERSON<|>A researcher involved in studies on heart rate in hypertension>  \n##  \n(\"entity\"<|>SATHYAMURTHY I<|>PERSON<|>A researcher involved in studies on heart rate in hypertension>  \n##  \n(\"entity\"<|>孙宁玲<|>PERSON<|>A researcher involved in studies on the heart rate status of Chinese hypertensive patients>  \n##  \n(\"entity\"<|>霍勇<|>PERSON<|>A researcher involved in studies on the heart rate status of Chinese hypertensive patients>  \n##  \n(\"entity\"<|>黄峻<|>PERSON<|>A researcher involved in studies on the heart rate status of Chinese hypertensive patients>  \n##  \n(\"entity\"<|>GRASSI G<|>PERSON<|>A researcher involved in studies on sympathetic nerve traffic activation in essential hypertension>  \n##  \n(\"entity\"<|>PISANO A<|>PERSON<|>A researcher involved in studies on sympathetic nerve traffic activation in essential hypertension>  \n##  \n(\"entity\"<|>BOLIGNANO D<|>PERSON<|>A researcher involved in studies on sympathetic nerve traffic activation in essential hypertension>  \n##  \n(\"entity\"<|>SERAVALLE G<|>PERSON<|>A researcher involved in studies on the sympathetic nervous system and hypertension>  \n##  \n(\"entity\"<|>ESLER M<|>PERSON<|>A researcher involved in studies on the evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension>  \n##  \n(\"entity\"<|>LAMBERT G<|>PERSON<|>A researcher involved in studies on the evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension>  \n##  \n(\"entity\"<|>ESLER D<|>PERSON<|>A researcher involved in studies on the evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension>  \n##  \n(\"entity\"<|>ZHAO MX<|>PERSON<|>A researcher involved in studies on the effect of resting heart rate on the risk of all-cause death in Chinese patients with hypertension>  \n##  \n(\"entity\"<|>ZHAO Q<|>PERSON<|>A researcher involved in studies on the effect of resting heart rate on the risk of all-cause death in Chinese patients with hypertension>  \n##  \n(\"entity\"<|>ZHENG M<|>PERSON<|>A researcher involved in studies on the effect of resting heart rate on the risk of all-cause death in Chinese patients with hypertension>  \n##  \n(\"entity\"<|>ZHANG M<|>PERSON<|>A researcher involved in studies on the association of resting heart rate and cardiovascular disease mortality in hypertensive and normotensive rural Chinese>  \n##  \n(\"entity\"<|>HAN C<|>PERSON<|>A researcher involved in studies on the association of resting heart rate and cardiovascular disease mortality in hypertensive and normotensive rural Chinese>  \n##  \n(\"entity\"<|>WANG C<|>PERSON<|>A researcher involved in studies on the association of resting heart rate and cardiovascular disease mortality in hypertensive and normotensive rural Chinese>  \n##  \n(\"entity\"<|>SWEDBERG K<|>PERSON<|>A researcher involved in studies on Ivabradine and outcomes in chronic heart failure>  \n##  \n(\"entity\"<|>KOMAJDAM<|>PERSON<|>A researcher involved in studies on Ivabradine and outcomes in chronic heart failure>  \n##  \n(\"entity\"<|>B?HM M<|>PERSON<|>A researcher involved in studies on heart rate as a risk factor in chronic heart failure>  \n##  \n(\"entity\"<|>TSAI ML<|>PERSON<|>A researcher involved in studies on optimal heart rate control in decompensated heart failure with reduced ejection fraction>  \n##  \n(\"entity\"<|>LIN SI<|>PERSON<|>A researcher involved in studies on optimal heart rate control in decompensated heart failure with reduced ejection fraction>  \n##  \n(\"entity\"<|>KAO YC<|>PERSON<|>A researcher involved in studies on optimal heart rate control in decompensated heart failure with reduced ejection fraction>  \n##  \n(\"entity\"<|>KJEKSHUS JK<|>PERSON<|>A researcher involved in studies on the importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials>  \n##  \n(\"entity\"<|>CUCHERAT M<|>PERSON<|>A researcher involved in studies on the quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction>  \n##  \n(\"relationship\"<|>GRANGER CB<|>N ENGLJ MED<|>Granger CB published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ALEXANDER JH<|>N ENGLJ MED<|>Alexander JH published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>MCMURRAY JJ<|>N ENGLJ MED<|>McMurray JJ published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>GIUGLIANO RP<|>N ENGLJ MED<|>Giugliano RP published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>RUFF CT<|>N ENGLJ MED<|>Ruff CT published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>BRAUNWALD E<|>N ENGLJ MED<|>Braunwald E published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>STEFFEL J<|>N ENGLJ MED<|>Steffel J published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>COLLINS R<|>N ENGLJ MED<|>Collins R published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ANTZ M<|>N ENGLJ MED<|>Antz M published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>KIRCHHOF P<|>N ENGLJ MED<|>Kirchhof P published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>CAMM AJ<|>N ENGLJ MED<|>Camm AJ published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>GOETTE A<|>N ENGLJ MED<|>Goette A published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>PALATINI P<|>N ENGLJ MED<|>Palatini P published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ROSEI EA<|>N ENGLJ MED<|>Rosei EA published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>CASIGLIA E<|>N ENGLJ MED<|>Casiglia E published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>DALAL J<|>N ENGLJ MED<|>Dalal J published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>DASBISWAS A<|>N ENGLJ MED<|>Dasbiswas A published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>SATHYAMURTHY I<|>N ENGLJ MED<|>Sathyamurthy I published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>孙宁玲<|>N ENGLJ MED<|>孙宁玲 published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>霍勇<|>N ENGLJ MED<|>霍勇 published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>黄峻<|>N ENGLJ MED<|>黄峻 published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>GRASSI G<|>N ENGLJ MED<|>Grassi G published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>PISANO A<|>N ENGLJ MED<|>Pisano A published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>BOLIGNANO D<|>N ENGLJ MED<|>Bolignano D published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>SERAVALLE G<|>N ENGLJ MED<|>Seravalle G published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ESLER M<|>N ENGLJ MED<|>Esler M published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>LAMBERT G<|>N ENGLJ MED<|>Lambert G published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ESLER D<|>N ENGLJ MED<|>Esler D published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ZHAO MX<|>N ENGLJ MED<|>Zhao MX published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ZHAO Q<|>N ENGLJ MED<|>Zhao Q published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ZHENG M<|>N ENGLJ MED<|>Zheng M published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>ZHANG M<|>N ENGLJ MED<|>Zhang M published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>HAN C<|>N ENGLJ MED<|>Han C published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>WANG C<|>N ENGLJ MED<|>Wang C published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>SWEDBERG K<|>N ENGLJ MED<|>Swedberg K published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>KOMAJDAM<|>N ENGLJ MED<|>Komajdam published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>B?HM M<|>N ENGLJ MED<|>B?hm M published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>TSAI ML<|>N ENGLJ MED<|>Tsai ML published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>LIN SI<|>N ENGLJ MED<|>Lin SI published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>KAO YC<|>N ENGLJ MED<|>Kao YC published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>KJEKSHUS JK<|>N ENGLJ MED<|>Kjekshus JK published research in N EnglJ Med<|>5>  \n##  \n(\"relationship\"<|>CUCHERAT M<|>N ENGLJ MED<|>Cucherat M published research in N EnglJ Med<|>5>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_47b64b7757f534671a423bdc176f95413e2acd3fdb9687cce5514857165242dc_v2"}